| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 2, 2022
New directors join Coeptis' Board following completion of merger with Bull Horn Holdings and advancement to Nasdaq WEXFORD, Pa., Nov. 2, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc....
-
Oct 31, 2022
Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ --...
-
Sep 21, 2022
SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022
-
May 17, 2022
Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and...
Apr 19, 2022Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancerCoeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq:...
-
Apr 13, 2022
Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD
-
Jan 20, 2022Newly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI)
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board...
-
Aug 19, 2021Technologies include CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a pharmaceutical company focused on the development of innovative technologies designed to disrupt conventional treatment paradigms and improve patient...
-
Jul 9, 2021New Corporate Name and Updated Stock Ticker Symbol Highlight Company's Brand Transformation
Vinings Holdings, Inc. (OTC PINK: NDYN), today announced that it is changing its corporate name to "Coeptis Therapeutics, Inc." and updating its ticker symbol to "COEP" effective Monday, July 12,...
-
May 18, 2021Technologies being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) Platform
Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), today announced entry into two separate exclusive option agreements with VyGen-Bio, Inc., a...